Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi

  • Post published:October 10, 2024
  • Post category:Analysis/News
Read more about the article Psychedelic Funding Update: Q3 2024

Psychedelic Funding Update: Q3 2024

  • Post published:October 8, 2024
  • Post category:Analysis/Pα+
Read more about the article The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

  • Post published:September 30, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Real-World Data Reveals Variability in Access to, and Use of, Spravato

Real-World Data Reveals Variability in Access to, and Use of, Spravato

  • Post published:September 13, 2024
  • Post category:Analysis/News/Pα+
Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

  • Post published:August 28, 2024
  • Post category:Analysis/News/Pα+
Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

  • Post published:August 22, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

  • Post published:August 15, 2024
  • Post category:Analysis/News/Pα+
Read more about the article Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

  • Post published:August 13, 2024
  • Post category:Analysis/News/Pα+
Read more about the article BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

  • Post published:August 9, 2024
  • Post category:Analysis/News
Read more about the article Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week

Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week

  • Post published:August 6, 2024
  • Post category:Analysis/News

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More